Pediatric Influenza: Advances in Vaccine Technology and Their Impact on Clinical Practice

1.50 CME
1.50 CME WITH ABP MOC
90 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Pediatric Influenza: Advances in Vaccine Technology and their Impact on Clinical Practice

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Seqirus USA Inc.


Activity Description

In the United States, the incidence of pediatric influenza ranges from 20% to 30% annually. Because children represent key vectors for spreading the disease in the community, it is imperative that influenza vaccination rates among children increase. Influenza vaccination can reduce the risk of influenza-related admission to the intensive care unit in children by 74%, as well as significantly reduce a child’s risk of death from influenza. There are currently 2 Food and Drug Administration-approved influenza vaccine production technologies: one that is egg-based and another that is cell-based. Although the egg-based approach is the more common and traditional technology, cell-based influenza vaccines possess several advantages over egg-based vaccines. In this educational program, experts will review the differences between these vaccine technologies and the clinical and real-world data regarding their efficacy in terms of their ability to prevent influenza and reduce hospitalizations and emergency department visits.


Target Audience

The intended audience for this activity is family medicine physicians, pediatricians, and other health care professionals involved in the management of pediatric patients with influenza.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden of pediatric influenza, as well as the need to increase vaccination rates among this patient population.
  • Compare influenza vaccines in terms of their technology, efficacy, safety, and administration in pediatric patients.
  • Assess the use of pediatric influenza vaccines in real-world applications and how this information can be applied to clinical practice.

Activity Chair

Andrew T. Pavia, MD, FAAP, FIDSA
George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT


Faculty

C. Buddy Creech, MD, MPH, FAAP, FPIDS
Director, Vanderbilt Vaccine Research Program
Edie Carell Johnson Chair in Pediatrics
Professor, Pediatric Infectious Diseases
President-Elect, Pediatric Infectious Diseases Society (PIDS)
Vanderbilt University School of Medicine and Medical Center
Nashville, TN

Natasha B. Halasa, MD, MPH, FAAP, FIDSA, FPIDS
Craig Weaver Professor of Pediatrics
Pediatric Infectious Diseases
Vanderbilt University Medical Center
Nashville, TN


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abp mocSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.50 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. 

This enduring material is approved for 1 year from the date of original release, November 30, 2021 to November 29, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant relationship(s)

C. Buddy Creech, MD, MPH, FAAP, FPIDS
Consultant: Altimmune, Astellas
Independent Research Contractor: Merck

Natasha B. Halasa, MD, MPH, FAAP, FIDSA, FPIDS
Grant Support: Sanofi

Andrew T. Pavia, MD, FAAP, FIDSA
Consultant: GlaxoSmithKline

Reviewer reports the following relevant relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com